Chromosomal aberrations are a hallmark of human cancers, with complex cytogenetic rearrangements leading to genetic changes permissive for cancer initiation and progression. Protection of Telomere 1 (POT1) is an essential component of the shelterin complex and functions to maintain chromosome stability by repressing the activation of aberrant DNA damage and repair responses at telomeres. Sporadic and familial mutations in the oligosaccharide-oligonucleotide (OB) folds of POT1 have been identified in many human cancers, but the mechanism underlying how hPOT1 mutations initiate tumorigenesis has remained unclear. Here we show that the human POT1's OB-folds are essential for the protection of newly replicated telomeres. Oncogenic mutations in hPOT1 OB-fold fail to bind to single-stranded telomeric DNA, eliciting a DNA damage response at telomeres that promote inappropriate chromosome fusions via the mutagenic alternative non-homologous end joining (A-NHEJ) pathway. hPOT1 mutations also result in telomere elongation and the formation of transplantable hematopoietic malignancies. Strikingly, conditional deletion of both mPot1a and p53 in mouse mammary epithelium resulted in development of highly invasive breast carcinomas and the formation of whole chromosomes containing massive arrays of telomeric fusions indicative of multiple breakage-fusion-bridge cycles. Our results reveal that hPOT1 OB-folds are required to protect and prevent newly replicated telomeres from engaging in A-NHEJ mediated fusions that would otherwise promote genome instability to fuel tumorigenesis.
INTRODUCTION
The proper maintenance of a stable genome is essential for an individual's health and is paramount for faithful transmission of genetic information to future generations. One important mechanism that protects against the acquisition of an unstable genome is the proper function of telomeres, DNA-protein complexes that cap the ends of all eukaryotic chromosomes. 1 Mammalian telomeres are composed of repetitive TTAGGG DNA sequences synthesized by the enzyme telomerase, and a number of telomere-specific binding proteins that together safeguard telomeres from inappropriately activating DNA damage responses (DDR). 2, 3 Three sequence-specific telomere binding proteins are recruited to chromosomal ends: the duplex telomere repeat factors TRF1 and TRF2/RAP1, and the single-stranded (ss) telomere DNA binding protein Protection of Telomere 1 (POT1). POT1 forms a heterodimer with TPP1, and this heterodimer acts to regulate telomerase access to telomeres. [4] [5] [6] [7] [8] [9] TPP1 directly recruits telomerase to telomeres to enable telomere elongation, while POT1 negatively regulates telomere length by modulating telomerase access to telomeres through physical interaction of its highly conserved oligonucleotide/oligosaccharide binding (OB) folds with the ss G-overhang. [10] [11] [12] The mouse genome encodes two mPot1 genes, mPot1a and mPot1b, while a single human hPot1 is postulated to possess the functions of both mouse proteins. [13] [14] [15] [16] Removal of mPOT1a, hPOT1 (and to a lesser extent mPot1b) results in activation of a potent Ataxia telangiectasia and Rad3 (ATR)-dependent DDR, marked by recruitment of replication protein A (RPA), the sensor of the ATR pathway, to telomeres. This DDR also promotes activation of downstream signalling kinases, including Chk1, and marks dysfunctional telomeres as double-stranded breaks (DSBs).
14,17-20 mPOT1b's main function is to inhibit 5' nucleolytic processing of the telomeric C-strand, limiting the length of the 3' ss telomeric overhang. 13, 21 Highly proliferative mouse cells lacking mPot1b generate long stretches of ss telomeric DNA that activates p53-dependent DNA damage checkpoint responses to diminish stem cell proliferation, consequences of which include bone marrow (BM) failure and compromised organismal lifespan. 13, 22, 23 These results reveal essential roles for POT1 proteins in preventing inappropriate activation of the ATR-mediated, p53-dependent DNA damage signalling at telomeres.
POT1 proteins are also required to prevent inappropriate repair of dysfunctional telomeres. Activation of the ATR kinase, and generation of 3' ss overhangs, are both essential to promote alternative non-homologous end joining (A-NHEJ)-mediated repair of mouse telomeres devoid of Pot1a/b. [24] [25] [26] [27] [28] A-NHEJ is a microhomology-based error-prone repair pathway that fosters the generation of gross chromosomal abnormalities, including large deletions, insertions and translocations, thereby increasing genome instability. 27, 29, 30 This pathway has emerged as the primary DNA repair pathway in several human cancers. 31, 32 We have shown previously that deletion of mPot1a and mPot1b in conditional knockout mouse models activates a potent p53-dependent DDR, resulting in cellular senescence and apoptosis. 14, 22, 23, 33 In the absence of a functional p53 pathway, loss of mPOT1a or mPOT1b promotes end-to-end chromosome fusions and cancer formation, suggesting that POT1 proteins are critically important for preventing the initiation of tumour promoting genomic instability. In accord with our mouse studies, whole genome sequencing efforts have revealed that recurrent hPot1 mutations are present at high frequencies in patients with chronic lymphocytic leukemia (CLL) and familial melanomas (FM). [34] [35] [36] [37] These results highlight the importance of hPOT1 in maintaining genome stability to prevent the onset of tumorigenesis. However, it is unclear how hPOT1 exerts these critical protective functions.
In our current study, we investigated how hPOT1 OB-fold mutations promote tumorigenesis. We demonstrated that mutant hPOT1 elicits a DDR at telomeres that is repaired through the error-prone A-NHEJ DNA repair pathway. When transduced into hematopoietic stem cells, mutant hPOT1 initiates transplantable myeloid malignancies and increased telomere lengths during long-term culture. Conditional deletion of both mPot1a and p53 from mouse mammary epithelium resulted in development of highly invasive breast tumours that were highly genomically unstable, bearing impressive arrays of telomeric signals indicative of multiple breakage-fusion-bridge (BFB) cycles. Finally, we show that the OB-folds of hPOT1 are required to protect newly replicated telomeres from chromosome fusions. Our results reveal important roles for hPOT1 OB-fold mutations in promoting both genome instability and increased telomere elongation to favour tumour initiation.
RESULTS
hPot1 OB-fold mutations induce a DNA damage response at telomeres Recent whole-genome and exome sequencing have identified recurrent hPot1 mutations in~9% of the most aggressive form of CLL, making hPot1 the second most frequently mutated gene to date identified in CLL. 35, 36 In FM, hPot1 is also the second most frequently mutated, high penetrance gene reported thus far, representing~30% of all FM cases. 36, 37 hPOT1 is thus the first shelterin component found to be mutated in diverse human cancers. CLL and FM hPOT1 somatic mutations cluster primarily within the two OB-folds and are predicted to disrupt phylogenetically conserved amino acid residues (Figure 1a ; Supplementary Figure 1A ). For example, crystal structure analyses revealed that two residues mutated in cancer, Tyr89 and Gln94, interact with the fourth G residue in the TTA 3 G 4 GG telomeric repeat. 11 The aromatic phenol ring of Tyr89 stacks with G4 and A3, providing non-specific interactions. In contrast, the side chain of Gln94 mediates two hydrogen-bonding interactions with G4, thus specifically recognizing a G in this position. Mutating these residues to other amino acids is predicted to interfere with POT1 OB-fold's hydrogen bonding with telomeric DNA (Figure 1b ; Supplementary Figure 1B ). To test this hypothesis, we used site-directed mutagenesis to generate hPot1 CLL and FM point mutations Y36N, Y89C, Y223C and S270N. Because Q94 is a shared amino acid residue between both CLL and FM, we mutated it to an alanine, which is predicted to abolish hPOT1's interaction with G4 ( Figure 1b) . We first examined whether these hPOT1 OB-fold mutants are able to bind to ss (TTAGGG) 4 oligos in vitro. Four hPOT1 mutants displayed either markedly reduced binding (S270N), or were completely unable to bind to ss telomeric oligos (Y89C, Q94A, Y223C) (Figure 1c ). The hPOT1 Y36N mutant bound to ss telomeric DNA with high affinity (Figure 1c) , and behaved like WT hPOT1 in subsequent telomeric assays (data not shown). These results demonstrate that tumorigenic hPOT1 OB-fold mutations disrupt binding to ss telomeric DNA in vitro, supporting the conclusions drawn from previous studies. [33] [34] [35] Localization of both mouse and human POT1 to telomeres in cells requires interaction with its heterodimeric partner TPP1, while the POT1 OB-folds appear dispensable for in vivo telomere localization. [13] [14] [15] 38 To determine whether OB-fold mutations disrupted binding to TPP1, we subjected the HA-tagged hPOT1 mutants to immunoprecipitation (IP) experiments with FlaghTPP1. We found that all hPOT1 OB-fold mutants interact with hTPP1 as robustly in vitro as WT hPOT1, indicating that these mutations do not disrupt TPP1-POT1 interaction (Figure 1c ). In addition, stabilization of hPOT1 requires binding to hTPP1, since WT hPOT1 is unstable in the presence of a hTPP1
ΔRD mutant that it cannot bind to ( Figure 1c) . Immunofluorescence microscopy confirmed that all hPOT1 OB-fold mutants are stably expressed and readily localized to telomeres in both U2OS and IMR90 cells ( Supplementary Figures 2A-C and 3A-C) . Since mammalian POT1 proteins function to repress a DDR at telomeres, we next asked whether the hPOT1 OB-fold mutations abolish this function, using the dysfunctional telomere-induced DNA damage foci (TIF) assay to monitor recruitment of DNA damage marker γ-H2AX to telomeres in both U2OS and IMR90 cell lines. Greater than five TIFs per cell were observed in 35 Figures 3A and D) . Expression of hPOT1 OB-fold mutations resulted in the generation of end-to-end chromosomal fusions in 1.5-2.5% of all IMR90 chromosomes scored; telomeric signals were present at some sites of fusion (Figures 1f and g ). Taken together, these results confirm previous findings in human tumours that hPOT1 OB-fold mutations activate DNA damage signalling at telomeres. [35] [36] [37] While fusions were rare in human tumours, our results suggest that inappropriate repair of telomeres lacking functional hPOT1 OB-folds promoted formation of fused chromosomes.
hPOT1 OB-fold mutants promote A-NHEJ-mediated chromosomal fusions hPot1 mutations in CLL and FM are heterozygous mutations. To determine whether mutant hPOT1 proteins function as a dominant negative and require the presence of the WT hPOT1 allele to elicit chromosome fusions, we generated CAG-Cre Expression of all hPot1 alleles together with hTpp1 in CAG-Cre ER -mPot1a Δ/Δ ; mPot1b −/− MEFs promoted efficient localization of hPOT1 to mouse telomeres (Supplementary Figure 4C) .
We found that only expression of WT hPot1 was able to repress TIF formation, while 60% of cells expressing all hPot1 OB-fold mutants examined display increased TIF formation (Figure 2a) . To examine the role of OB-fold mutants in repressing a DDR at telomeres, we utilized the mPOT1 F62A OB-fold mutant, which we have previously shown to disrupt ss telomeric DNA binding and elicits a potent DDR at telomeres (Supplementary Figures 1A and B ; mPot1b −/− MEFs was unable to repress ATR-dependent DDR, and similar to the hPot1 OB-fold mutants, also generated chromosome-type and chromatidtype fusions involving~10% of all chromosome ends, some with and some without telomeres at fusion sites. In addition, sister chromatid fusions (sister unions), a hallmark of telomeres devoid of functional POT1, were also observed (Figure 2b ; Supplementary  Figures 5A and B) . Expression of WT mPot1a repressed activation of the DDR while expression of WT mPot1a, mPot1b and hPot1 reduced chromosome fusion frequencies to background levels ( Figure 2b, Supplementary Figures 5A and 5B). These results suggest that while mPOT1b plays a reduced role in preventing activation of a DDR at telomeres, it is required to prevent inappropriate repair of telomere ends. In addition, our data suggest that hPOT1 OB-fold mutants do not require the presence of WT hPOT1 to render telomeres dysfunctional; these mutants are fully capable of eliciting a DDR that initiates aberrant DNA repair and the generation of chromosome fusions.
Uncapped telomeres can be repaired either by the error-prone non-homologous end joining (NHEJ) or the error-free homologous recombination repair pathways. NHEJ can proceed either by the Classic, Lig4-dependent pathway (C-NHEJ), or by the Alternative, LIG 4-independent, PARP1-dependent NHEJ (A-NHEJ) pathway. We have previously shown that mPOT1a/b are required to protect the ss G-overhang from engaging in A-NHEJ mediated DNA repair. 24 To determine whether the chromosome fusions observed upon expression of the hPOT1 mutants are generated by A-NHEJmediated repair, we expressed mPot1a F62A or mPot1b F62A in Ku70
MEFs defective in C-NHEJ, but not A-NHEJ-mediated DNA repair. 40, 41 TIFs and end-to-end chromosomal fusions were both prominent in Ku70 Most hPot1 OB-fold mutations inhibit telomerase activity in vitro but promote telomere elongation in vivo hPOT1 has been shown to inhibit telomerase activity in vitro by competing for access to the 3' end of G-rich ss telomeric DNA. 42 Since hPOT1 OB-fold mutants interact poorly with ss telomeric DNA (Figure 1c ), we hypothesized that mutations in the hPOT1 OB-fold might enable increased telomerase access to the 3' G-rich overhang, promoting telomere elongation. To test this hypothesis, we performed direct telomerase primer extension assays using HEK 293T cells transiently co-expressing telomerase and either WT or mutant hPOT1. We observed the characteristic decrease of telomerase activity in the presence of WT hPOT1 (Figure 3a) . In addition, we observed that the hPOT1 F62A, Q94A, Y223C and S270N mutants were all as efficient as WT hPOT1 in inhibiting telomerase activity. However, we observed a~10 and~60% defect in telomerase inhibition in the presence of hPOT1 Y36N and hPOT1 Y89C , respectively, suggesting that at least in vitro the DNAbinding defects of these two mutants correlate with their diminished ability to inhibit telomerase (Figures 3a and b) . The differences in the abilities of the hPOT1 mutants to inhibit telomerase do not arise from differences in hPOT1 expression, since hPOT1 mutant expression is uniform across the various transfections (Figure 3c) .
We next asked whether expression of hPOT1 OB-fold mutants affected telomere length maintenance in vivo, using telomerase positive HT1080 cells. We found that upon serial passaging, expression of all hPot1 mutants resulted in progressive telomere elongation, from an average telomere length of~4.5 kb to 9.5 kb over 75 population doublings (Figure 3d ; Supplementary Figures  7A and B) . As a negative control, telomere elongation was not observed in HT1080 cells expressing vector control, the hTpp1 OB WT construct, 43 nor in serially passaged IMR90 cells expressing WT hPot1 or mutants (Supplementary Figures 7B-D) . These findings suggest that while the majority of hPot1 OB-fold mutants were able to inhibit telomerase activity in an in vitro assay, in long-term passaging experiments all displayed increased telomere length elongation similar to the hPot1 mutant human tumours [35] [36] [37] or cells expressing the hPot1 ΔOB mutant, which is unable to negatively regulate telomerase access to telomeres. 44 Finally, we asked whether hPot1 mutations impacted upon the ability for telomerase to be recruited to telomeres by performing a modified immunofluorescence/FISH-based telomerase recruitment assay. 12 HeLa cells expressing the catalytic subunit of telomerase (TERT), the RNA subunit of telomerase (TR) and either WT or mutant hPot1 were fixed and stained for telomeres and TR. While localization of TR to telomeres was reduced when TPP1 was not co-expressed in this assay, we found that endogenous TPP1 was sufficient to permit TR localization to 3-4 telomeres in the majority of cells examined. The number of TR positive foci per cell, and the percentage of telomeres co-localizing with TR, was similar in cells expressing either WT or mutant hPot1 (Figure 3e ; Supplementary Figures 7C and D) . These results suggest that Figure 3 . hPOT1 OB-fold mutants do not inhibit in vitro telomerase activity and promote telomere length elongation in vivo. (a) Direct telomerase primer extension assays using lysates from HEK 293T cells co-transfected with TR, TERT, hPOT1 and hTPP1 plasmids. ' − ' indicates a transfection excluding the hPOT1-encoding plasmid. (b) Quantification of telomerase activity data from two independent experiments. The horizontal lines show telomerase activity in the absence (upper line) versus presence (lower line) of wild-type HA-hPOT1 overexpression. All data were normalized to the telomerase activity of the reaction containing overexpressed wild-type HA-hPOT1. Error bars indicate the s.e.m. of experiments done in duplicate. (c) Immunoblot of the telomerase extracts used in (A) probed with anti-FLAG (to detect TERT and hTPP1) and anti-HA (to detect hPOT1) antibodies. A non-specific (ns) band in the immunoblot appears at~40 kDa with the anti-HA antibody. (d) TRF Southerns to analyse telomere length in serially passaged HT1080 cells expressing the indicated DNAs. Genomic DNAs from cells isolated at population doublings (PD) 0, 25, 50 and 75 were fractionated with a clamped homogenous electric field (CHEF) gel. In-gel hybridization was performed using a radiolabelled (CCCTAA) 4 probe to detect total telomeric repeats. Re-hybridization with an Alu repetitive DNA probe was used to quantitate DNA loading. Molecular weight markers are on the right. (e) Co-localization of human telomerase RNA (TR) on telomeres in HeLa cells overexpressing hTert, hTR and WT or mutant hPot1. Telomeres (green) were labeled with PNA probe Cy3-OO-(CCCTAA) 4 and TR (red) was visualized by RNA-FISH with Cy5-TR probes. Nuclei were stained with DAPI (blue).
hPOT1 OB-fold mutations do not impact upon telomerase recruitment to telomeres.
Reconstitution of hPot1
Y223C expressing hematopoietic cells in SCID mice promotes the formation of transplantable hematopoietic malignancy Our data support the notion that hPOT1 OB-fold mutants promote both genomic instability through loss of ATR-mediated DDR repression and telomere elongation via loss of telomerase regulation, both of which are causal for cancer development. To further determine how these mutations might promote tumorigenesis, we analysed the CLL hPOT1 Y223C mutation in greater detail, since this recurrent mutation has been identified in several CLL patients. 35 We generated MSCV-hPot1 Y223C -IRES-GFP and MSCV-hPot1
WT -IRES-GFP retroviral vectors, and along with hTpp1, transduced them independently into murine p53 +/ − fetal liver cells to investigate the impact of mutant hPot1 expression in the hematopoietic system. Both WT hPOT1 and hPOT1 Y223C readily localized to telomeres of mouse fetal liver cells, but only hPOT1 Y223C initiated TIF formation (Figures 4a and b,  Supplementary Figure 8A) . Retrovirally infected fetal liver cells were injected into lethally irradiated SCID mice, and serial bleeds were performed to monitor GFP expression as a marker of BM engraftment. In 4/8 recipient mice, hPOT1
Y223C -GFP levels increased steadily post transplantation, while hPOT1
WT -GFP levels 
Y223C -GFP conferred a positive selective advantage to irradiated recipients (Figure 4c ). BM cells isolated from stably engrafted mice after 30 weeks displayed end-to-end chromosomal fusions, and RT-PCR analysis revealed that these cells express the hPot1 Y223C transgene (Figures 4d and e;  Supplementary Figure 8B ). Histological analysis revealed that myeloid dysplasia was prominent in the BM of mice expressing hPot1 Y223C -GFP, with increased number of blasts, promyelocytes, myelocytes and metamyelocytes observed (Figure 4f) . FACS analysis revealed a significant increase in the CD11b + population (Figure 4g ), consistent with myeloid expansion. Examination of the liver and spleen revealed extensive CD11b + liver infiltration (Supplementary Figure 8C) . Importantly, this myeloid malignancy was transplantable into a second round of recipient SCID mice, forming CD11b + liver and splenic metastatic infiltrates (Figure 4h ). Taken together, these results suggest that expression of mutant hPot1 Y223C in hematopoietic cells promotes development of transplantable myeloid malignancy.
Deletion of mPot1a and p53 in the breast promotes the development of invasive breast carcinomas In addition to CLL and FM, our recent analysis of the TCGA database revealed that numerous missense somatic hPot1 mutations involving highly conserved amino acids in the hPOT1 OB-folds are present in diverse human cancers, including cancers of the breast, brain, lung, bladder, stomach and cervix (Supplementary Figure 9) . Since these mutations map to conserved amino acid residues throughout the OB-folds, it is likely that they also disrupt hPOT1 function. To understand mechanistically how POT1 protects telomeres to prevent initiation of solid tumours, we generated MMTV-Cre; mPot1a F/F mice to conditionally delete endogenous mPot1a in a temporal manner in mouse mammary epithelium. All MMTV-Cre; mPot1a F/F mice developed breast cancer after 24 months of age. Interestingly, 100% of these breast cancers lost p53 function, suggesting that deletion of mPot1a alone is insufficient to promote tumorigenesis. We hypothesized that breast cancer formation in this model system requires loss of both mPot1a and p53. To test this hypothesis, we generated MMTV-Cre; mPot1a F/F ; p53 F/+ and MMTVCre; mPot1a F/F ; p53 F/F mice. 100% of MMTV-Cre; mPot1a Δ/Δ ; p53 F/+ mice developed breast cancer, with a median tumour latency of 17 months, while 100% of MMTV-Cre; mPot1a Δ/Δ ; p53 F/F mice developed breast cancers by 8.4 months of age (Figure 5a ). Histological analysis revealed that the majority of these tumours were invasive breast adenocarcinomas (Figure 5b ) that stained positively with antibodies against cytokeratin markers CK5, 8 and 14 but not against ER-alpha (Figure 5c ). To further examine the p53 status of these tumours, we generated breast tumour cell lines and exposed them to 10 Gy ionizing radiation. While normal mouse mammary epithelial cells were able to induce expression of both p53 and its downstream target p21 following ionizing radiation exposure, p53 or p21 induction was not observed in any of the tumour cell lines, confirming loss of p53 function (Figure 5d ). Compared to telomere lengths observed in a mPot1a +/+ ; p53 −/− lymphoma, telomere restriction fragment (TRF) Southern analysis revealed that total telomere length was significantly increased and highly heterogeneous in all MMTV-Cre; mPot1a Δ/Δ ; p53 Δ/Δ tumours examined (Figure 5e ). Finally, TIF formation was also increased in these breast tumours (Figure 5f ). Taken together, these results suggest that compromised mPOT1a function, coupled with loss of p53, promotes formation of invasive breast adenocarcinomas.
MMTV-Cre; Pot1a
Δ/Δ ; p53 Δ/Δ breast tumours display massive telomere-DSB amplifications Compared to metaphase chromosome spreads derived from MMTV-Cre; p53 Δ/Δ lymphomas, PNA-telomere FISH revealed that 30% of MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours exhibit massive telomeric amplifications involving one, or at most a few, chromosomes. Extensive blocks of interstitial telomeric signals (ITS) encompassed large portions of individual chromosomes -or even entire chromosomes (Figure 6a; Supplementary Figure 10) . Such a striking telomeric phenotype has not been previously described in tumours from other mouse models of telomere dysfunction. Further, these cytogenetic anomalies were present in all metaphases examined, suggestive of ongoing instability: at least one was clonal and therefore transmissible (Supplementary Figure 10) . The presence of numerous blocks of ITS localized to only a few chromosomes is indicative of telomere fusions, occurring either as a result of mis-joining of two dysfunctional telomeres (telomere-telomere fusion), or fusion of a non-telomeric DSB end with an uncapped telomere (telomere-DSB fusion). 43 To ascertain the particular type of telomere fusion(s) generated in the MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours, we performed Chromosome Orientation (CO)-FISH, a strand-specific cytogenetic methodology capable of distinguishing leading (C-rich) versus lagging-strand (G-rich) telomeres. 43, 44 CO-FISH revealed that some of the ITS, including those present at centromeres of Robertsonian translocations, resulted from telomere-telomere fusions; that is, red/green telomeric signals with no spaces in between (Figure 6b ; Supplementary Figures 10A-C) . However, the vast majority of ITS consisted of extensive blocks of G-rich or C-rich telomeric DNA interspersed with DAPI stained non-telomeric DNA (Figure 6b ; Supplementary Figures 10A) , a pattern most consistent with multiple telomere-DSB fusions (all red signals on one side and all green on the other). The source of the ITS could be either the ends of other chromosomes, or the result of amplification of the telomere fusion event. It is highly unlikely that the majority of ITS was derived from other chromosomal ends, as telomere-free ends were not increased in MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours (Figures 6a and b; Supplementary Figures 10B and C) . We have previously shown that fusion of telomeres devoid of mPOT1a promotes generation of dicentric chromosomes, which form anaphase bridges.
14 Depending on how the anaphase bridge resolves during cytokinesis, breakage can occur within telomeric regions -or anywhere along the chromosome -setting up cycles of BFB to fuel a highly unstable genome. Therefore, either a single telomere-telomere fusion, or a telomere-DSB fusion, could produce a dicentric chromosome, thereby triggering multiple rounds of BFB cycles and amplifying the telomeric signals.
To determine whether the extensive blocks of ITS observed in POT1 mutant tumours originated from a telomere-DSB fusion between two chromosomes or a telomere-telomere fusion between two sister chromatids (sister union), we employed Spectral Karyotyping (SKY) to identify individual mouse chromosomes. Not surprisingly, SKY revealed chromosomal duplications and multiple non-reciprocal translocations in breast tumour # 3327 (Figures 6c and d; Supplementary Figure 10D ). More interesting was the observation that in this tumour, one of the amplified ITS regions was clonal and associated with chromosome 12, indicating that this particular ITS block likely resulted from a sister union that was subsequently amplified and duplicated via BFB cycles. We note that it was not possible to definitely ascertain the origin of the long telomeric blocks due to the repetitive (nonstaining) nature of telomeric DNA. In support of repeated BFB cycles as the mechanism responsible for generating the aberrant ITS observed in MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours, increased numbers of anaphase bridges and micronuclei were also observed (Figure 6e) . Additionally, CO-FISH revealed a ~fivefold increase in the number of telomere sister chromatid exchanges (T-SCEs) 43 in these tumours (Figure 6f ).
hPOT1 OB-folds protect newly synthesized telomeres from chromosome fusions The aberrant chromosomes in MMTV-Cre; Pot1a
; p53 Δ/Δ breast tumours bearing multiple blocks of ITS and increased T-SCEs observed are reminiscent of a small percentage of aberrant chromosomes showing similar phenotypes generated in the absence of the Apollo/SNM1b nuclease, 45 suggesting that the cytogenetic aberrations might be associated with DNA replication. Immediately after DNA replication, leading-strand telomeres are initially blunt ended, while lagging-strand telomeres possess a short overhang due to placement and/or removal of the terminal RNA primer. We have shown previously that the 5' to 3' Apollo/ SNM1B exonuclease is recruited to telomeres to process the 5' C-strands of leading-strand telomeres to generate the 3' ss telomeric overhangs, to which POT1-TPP1 can bind and prevent leading-strand telomere fusion. 45 Apollo/SNM1B was not required at lagging strand telomeres because these already possess a minimal 3' overhang after DNA replication, to which POT1-TPP1 can bind to and protect. 45 We used Apollo/SNM1B null MEFs to probe the protective functions of the POT1 OB-fold after DNA replication, postulating that an intact POT1 OB-fold is required for binding and protection of the 3' ss overhangs of lagging-strand telomeres. Increased chromatid aberrations involving the laggingstrand telomere (as well as sister chromatid fusions) should be observed in Apollo/SNM1B −/− MEFs expressing mutant hPot1. On the other hand, the blunt-ended leading-strand telomeres should be relatively unaffected by the presence of POT1 OB-fold mutations. To test this hypothesis, we expressed WT mPot1a, WT mPot1b, WT hPOT1 with hTPP1, mPot1a F62A , mPot1b F62A and hPOT1 OB-fold mutants in Apollo/SNM1B −/− MEFs. Robust TIF formation was observed in cells expressing both mouse and human Pot1 OBfold mutants but not any of the WT Pot1 alleles (Figures 7a and b) . Greater than 90% of all chromosomal aberrations observed in Apollo/SNM1B −/− MEFs expressing mutant mouse and human Pot1 DNA were end-to-end chromosome fusions with telomeres at fusion sites (Figures 7c and d; Supplementary Figures 11A and B) . Aberrant chromosomes containing amplified blocks of ITS similar to those observed in the MMTV-Cre; Pot1a
Δ/Δ breast tumours were prominent in cells expressing all Pot1 OB-fold F/F , p53 F/F mice. Genomic DNAs from tumours were fractionated with a clamped homogenous electric field (CHEF) gel. In-gel hybridization was performed using a radiolabeled (CCCTAA) 4 mutants (Figures 7e and f; Supplementary Figures 11A and B) . In addition, a small percentage of the telomere fusions were of the chromatid-type (Figure 7c ; Supplementary Figures 11C and D) . Unlike the relative paucity of lagging-strand chromatid fusions and sister fusions observed in Apollo/SNM1B −/− MEFs expressing vector control, expression of all Pot1 OB-fold mutants resulted in increased number of chromatid fusions involving the lagging strand (Figure 7c; Supplementary Figures 11A, C and D) . These results suggest that an intact POT1 OB-fold is required to protect the lagging-strand after DNA replication, and highlight the importance of POT1 OB-folds in protecting newly synthesized lagging-strand telomeres from triggering a DDR that would otherwise stimulate the onset of BFB cycles.
DISCUSSION
Chromosomal structural aberrations are a hallmark of human cancers, with complex cytogenetic rearrangements leading to the amplification of oncogenes and deletion of tumour suppressors permissive for cancer initiation and progression. 46 These chromosomal aberrations could arise through the joining of chromosome ends lacking functional telomeres, resulting in the formation of dicentric chromosomes that subsequently undergo BFB cycles to generate an unstable genome. 47 In mammalian cells, the p53 tumour suppressor integrates signals emanating from DNA DSBs to initiate cellular checkpoint responses and the induction of a tumorigenic barrier. 48 Consequently, mice bearing dysfunctional telomeres are usually resistant to tumour development due to the activation of p53-dependent cellular senescence and apoptosis programmes. 22, 49, 50 In the absence of functional p53, telomerase deficiency 51 or deletion of shelterin components 14, 52 promotes telomere crisis and the formation of dysfunctional telomeres that are tumour promoting. hPOT1 germline mutations have been found in FM, glioma and cardiac angiosarcoma, 36, 37, 53, 54 while somatic mutations are found in CLL. 35 However, whether these mutations function as driver or passenger mutations is not known.
Here, we report on the effect of hPot1 OB-fold mutations in reconstituted cell lines and functional deletion of mPot1a in a mouse model of breast cancer. We found that expression of hPot1 CLL and FM mutations generated uncapped telomeres, which were subsequently repaired via the A-NHEJ error-prone DNA repair pathway. While the hPOT1 ΔOB mutant 44 and hPOT1 OB-fold cancer mutations 35, 54 are thought to function as dominant negatives, we show that when expressed in a mPot1a/mPot1b Pot1 OB-fold mutations unleash telomere instability P Gu et al 1947 null background, these mutants still negatively impact telomere functions. These results indicate that hPOT1 OB-fold mutants do not only function as dominant negatives but could also function as null alleles. p53 plays a major role in preventing cancers bearing unstable telomeres. For example, telomeres lacking TRF2 initiate a DDR that results in the activation of ATM, CHK2 and p53 to promote apoptosis or cellular senescence. In the p53 heterozygous hematopoietic compartment, we found that expression of mutant hPot1 Y223C contributes to myeloproliferation and myeloid transformation. hPot1 Y223C expressing BM cells were able to engraft ICR-SCID mice and confer transplantable myloproliferative malignancy. The increased ability of hPOT1 mutant cells to proliferate into infiltrating malignant clones upon secondary re-transplantation is consistent with an enhanced ability in these cells for telomerase to lengthen telomeres during cellular replication. This notion is supported by the observation that human cancers bearing hPOT1 OB-fold mutations, as well as breast tumours derived from our MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ mice, display increased telomere length. [35] [36] [37] 54 Since POT1 forms a heterodimer with TPP1, and together modulates telomerase processivity, 8, 9 we postulated that the hPOT1 OB-fold mutations are unable to limit telomerase access to the ss telomeric DNA. Our in vitro primer extension assays revealed that despite the observation that most hPOT1 mutants failed to bind to ss telomeric DNA in vitro, only two hPOT1 mutants analysed (hPOT1 Y36N and hPOT1 Y89C ) were unable to inhibit telomerase activity as well as WT hPOT1. In contrast, all hPOT1 OB-fold mutants promoted telomere length elongation in HT1080 cells, suggesting that these mutations impacted upon the ability to negatively regulate telomerase access to telomeres. The discrepancy between the in vitro and in vivo findings are likely technical. Because the primer concentration (1 μM) used in the in vitro assay is~100-fold greater than the dissociation constant of the POT1-DNA complex (~10 nM), 11, 55 it is reasonable that several of the (f) Examples of telomere-telomere and telomere-DSB fusions observed in Apollo −/− MEFs expressing mPot1 or hPot1 OB-fold mutants. CO-FISH was used to label telomere ends; FAM-OO-(TTAGGG) 4 (green) visualized leading-strand telomeres and Cy3-OO-(CCCTAA) 4 (red) the laggingstrand telomeres. Note: Both telomere-telomere and telomere-DSB fusions are shown.
DNA-binding defective hPOT1 mutants were still able to bind the DNA primer to inhibit telomerase activity.
Chromosomal fusions due to mPot1a deletion, or expression of hPot1 OB-fold mutants, utilize A-NHEJ-mediated repair, in agreement with our previous data demonstrating that mPot1a/b normally represses A-NHEJ-dependent DNA repair. 25 A-NHEJ uses regions of microhomology to align the DNA ends prior to Ligase 3-mediated end joining, and was initially thought to be a back-up repair pathway operating only in the absence of the classical, Ligase 4-dependent NHEJ. However, A-NHEJ appears to operate robustly even when C-NHEJ is functional. 27, 39 A-NHEJ is an inherently error-prone repair pathway and results in elevated genome instability. Better understanding of how the A-NHEJ repair pathway is normally repressed at telomeres by the POT1 proteins and how it becomes activated in precursor cancer cells devoid of POT1 function to drive tumour initiation and progression, is therefore critically important. We show that in MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours, massive blocks of amplified telomere signals are present on a few chromosomes. These cytogenetic aberrations are composed of both telomere-telomere and telomere-DSB fusions and likely arise from repeated rounds of BFB cycles. The generation of so many telomere-DSB fusions specifically localized to only a few chromosomes in the MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours is reminiscent of chromothripsis, a unique pattern of genomic rearrangements confined to one or a few chromosomes found in some cancer cells. 56 Chromothrypsis has been postulated to arise from increased BFB cycles initiated by chromosomes bearing dysfunctional telomeres. [56] [57] [58] [59] Sequestration of a broken acentric fragments into micronuclei and subsequent fragmentation and reassembly could result in the localization of cytogenetic aberrations to one or a few chromosomes. 60 However, while micronuclei and anaphase bridges were both observed in MMTV-Cre; Pot1a
Δ/Δ breast tumours, catastrophic shattering and random rejoining of chromosome fragments, a hallmark of chromothrypsis, was not observed. CO-FISH revealed that the blocks of telomere-DSB fusions in these tumours appear not to be oriented randomly.
Finally, we have shown previously that repair of uncapped telomeres in Apollo/SNM1B null MEFs takes place immediately following DNA replication. 45 Our data reveal that the OB-folds of mPot1a and hPOT1 are required to mediate this protective function. POT1 OB-fold mutants fail to protect lagging-strand telomeres and initiate the formation of massive blocks of ITS resembling those observed in the MMTV-Cre; Pot1a Δ/Δ ; p53 Δ/Δ breast tumours. Since these chromosomal telomere fusion phenotypes arose through replication of chromatid-type telomere fusions formed during and/or after DNA replication, the generation of these ITS in the absence of POT1 function likely requires ongoing DNA replication. We have previously shown that in mice, mPOT1a recruits ss binding protein 1 (SSB1) to telomeres to protect newly replicated telomeres. 61 We postulate that POT1 mutations or functional loss of POT1 prevents the recruitment of SSB1 to telomeres, resulting in increased telomere dysfunction during replication. Loss of telomere protective function generates both telomere-telomere and telomere-DSB fusions, thereby triggering multiple rounds of BFB cycles and amplifying the telomere signal. It is tempting to speculate that the failure of hPOT1 OB-fold mutations to modulate telomerase activity at telomeres in premalignant cancer cells, coupled with activation of a BFB cycle and enhanced A-NHEJ-mediated DNA repair, initiates rampant genome instability that favours tumour initiation and progression. 62 ; mPot1a F/F MEFs, were generated from the corresponding mice, immortalized with SV40-large T antigen (LT) and maintained in DMEM/high glucose media supplemented with 10% FBS. Human cell lines 293T, U2OS, HeLa, IMR90E6E7 and HT1080 were cultured in the same media. hPOT1 mutants were generated by site-directed mutagenesis (Stratagene, Sant Clara, CA, USA) and constructed in retrovirus expression vectors pQCXIP-puro, MSCV-IRES-GFP or MSCV-IRESPuro. All retroviruses were generated in 293T cells and infected target cells twice. Infection of mouse MEFs was performed with pCl-Eco help vector and infection of human cells was carried out with gal-pol and VSVG helper vectors. To efficiently express hPot1 DNA constructs in MEFs, viruses expressing hTpp1 was co-infected with viruses expressing hPot1. To delete mPot1a in CAG-Cre ER ; mPot1b −/− ; mPot1a F/F MEFs, cells were treated with 1 μM of 4-hydroxy-tamoxifen for 24 h to delete the floxed mPot1a allele. 0.5 ug/ml of PARP inhibitor PJ174 (CaliBiotech, Spring Valley, CA, USA) was used to inhibit PARP activity.
MATERIALS AND METHODS

Generation of mouse models of cancer
DNA binding assay, Co-IP experiments and antibodies used
To examine whether mutant hPOT1 was able to bind to ss telomeric DNA in vitro, 293T cells expressing WT or mutant HA-hPOT1 were lysed and incubated in TEB 150 buffer (50 mM Hepes pH 7.3, 150 mM NaCl, 2 mM MgCl 2 , 5 mM EGTA, 0.5% Triton X-100, 10% glycerol, proteinase inhibitors) overnight at 4°C with streptavidin-sepharose beads (Invitrogen, Carlsbad, CA, USA) coated with biotin-Tel-G (TTAGGG) 6 oligo. To probe for interactions between hTPP1 and hPOT1 mutants, 293T cells were transfected with pCl-Flag-hTPP1 and MSCV-IRES-GFP-hPOT1
WT or mutants. Lysates were incubated in TEB 150 buffer and anti-Flag antibody crosslinked to agarose beads (Sigma, St Louis, MO, USA, A2220) were used to Co-IP the Flag-hTPP1-HA-hPOT1 complex. After washing with TEB 150 buffer, the beads were analysed by immunoblotting. Antibodies used: antiFlag M2 (Sigma F3165); anti-HA (Sigma H3663); anti-Myc (Millipore, Billerica, MA, USA, #05-724); anti-phospho-Chk1 (Cell Signaling, Danvers, MA, USA, #2348); anti-phospho RPA2 (Bethyl, Montgomery, TX, USA, A300-245A); anti-p53 (Santa Cruz, Dallas, TX, USA, sc6243) and anti-p21 (Santa Cruz, sc6246).
Immunofluorescence and fluorescent in situ hybridization Cells grown in chambers were fixed for 10 min in 2% (w/v) sucrose and 2% (v/v) paraformaldehyde followed by PBS washes. Cells were blocked for 1 h in blocking solution (0.2% (w/v) fish gelatin and 0.5% (w/v) BSA in 1 × PBS. The cells were incubated with primary antibodies ON at 4°C. After 0.1% Triton-PBS washes, slides were incubated with the appropriate Alexa fluor secondary antibody for 1 h followed by washes in 1XPBS with 0.1% Triton. IF-FISH was carried out as described 14 using a 5′-Cy3-OO-(CCCTAA) 4 -3′ PNA telomere probe (PANAgene). DNA was counterstained with DAPI. Digital images were captured with a Nikon Eclipse 800 microscope utilizing an Andore CCD camera.
Chromosome analysis by telomere PNA-FISH and CO-FISH Cells were treated with 0.5 μg/ml of colcemid for 4-7 h before harvest. Chromosomes were fixed and telomere PNA-FISH performed with a 5′-Cy3-OO-(CCCTAA) 4 -3′ probe (PANAgene, Daejecon, Korea) as described. 14, 62, 63 For CO-FISH, metaphase spreads were incubated sequentially with 5′-Cy3-OO-(CCCTAA) 4 -3′ and 5′-FAM-CO-(TTAGGG) 4 -3′ probes. Images were captured on a Nikon Eclipse 800 microscope and processed with MetaMorph Premier (Molecular Devices, Sunnyvale, CA, USA).
TRF Southern 25 μg of total genomic human DNA was digested with RsaI and HinfI overnight and separated in 0.8% agarose gel at 85 V for 4.5 h. The gels were dried and denatured with 0.5 N NaOH, 1.5 M NaCl solution and neutralized with 3 M NaCl, 0.5M Tris-Cl, pH 7.0. The pre-hybridized gel in Church mix (0.5 M NaH 2 PO 4 , pH 7.2, 7% SDS) was hybridized Pot1 OB-fold mutations unleash telomere instability P Gu et al 1949
